Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Abl, Allarity, Astrazeneca, Atriva, Beximco, Biovaxys Technology, Ceapro, Cstone, Dotbio, Dynacure, Edigene, Eisai, Geovax Labs, Gritstone, Huyabio International, I-Mab, Jiangsu Recbio Technology, Johnson & Johnson, Jumpcan, Lotus, Merck, Newsoara, Nippon Shinyaku, Novan, Pharmamar, Revelar, Ridgeback, Shanghai, Sosei, Twist, University of Wisconsin-Madison, Valneva, Washington University School of Medicine, Zenith Epigenetics.
Aptose Biosciences Inc. has bought over the worldwide rights to Hanmi Pharmaceutical Co. Ltd.’s myeloid kinome inhibitor in a deal worth up to $420 million. Seoul, South Korea-based Hanmi has granted Aptose exclusive worldwide rights to HM-43239 for all indications. The candidate was developed for relapsed or refractory acute myeloid leukemia.
LONDON – Researchers have pinpointed a little-studied gene as responsible for doubling the risk of respiratory failure in COVID-19 and shown exactly how it exerts its effect. The gene, leucine zipper transcription factor like 1, is activated by a single base pair change on chromosome 3 that occurs in 60% of people of South Asian ancestry and 15% of people of European ancestry.
Sichuan Clover Biopharmaceuticals Inc. raised HK$2.03 billion (US$260.17 million) in its Hong Kong Stock Exchange debut. Shares closed at HK$12.98 (US$1.67) on Nov. 5 after trading as high as HK$13.56 earlier.
Four years after an initial investment, Takeda Pharmaceutical Co. Ltd. exercised its option to acquire Gammadelta Therapeutics Ltd. to develop gamma delta T-cell therapies for solid tumors and hematologic malignancies.
Investigators at Northwestern University’s Feinberg School of Medicine have used a new mouse model of Parkinson’s disease to confirm a causal role for mitochondrial dysfunction in Parkinson’s disease. More surprisingly, the same model has called into question previously uncontroversial notions about the motor features that are PD’s most conspicuous feature.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Aribio, Chinook, Innovation, Kazia, Kintor, Macrogenics, Nrx, Pfizer, RDIF, Sumitomo Dainippon, Vicore.
Ascletis Pharma Inc. has obtained the global development and commercialization right for ASC-22 (envafolimab) outside greater China from Suzhou-based Alphamab Oncology Co. Ltd. to treat viral diseases including hepatitis B.
RSS
